141 related articles for article (PubMed ID: 28743312)
1. Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan.
Zaidi SMA; Haseeb A; Habib SS; Malik A; Khowaja S; SaifUllah N; Rizvi N
BMC Res Notes; 2017 Jul; 10(1):313. PubMed ID: 28743312
[TBL] [Abstract][Full Text] [Related]
2. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
[TBL] [Abstract][Full Text] [Related]
3. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Chiang CY; Lin CJ
Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
[TBL] [Abstract][Full Text] [Related]
4. Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan.
Jabbar A; Phelan JE; de Sessions PF; Khan TA; Rahman H; Khan SN; Cantillon DM; Wildner LM; Ali S; Campino S; Waddell SJ; Clark TG
Sci Rep; 2019 Oct; 9(1):14996. PubMed ID: 31628383
[TBL] [Abstract][Full Text] [Related]
5. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
[TBL] [Abstract][Full Text] [Related]
7. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Multi-Drug Resistant
Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
Jabeen K; Shakoor S; Malik F; Hasan R
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():47-8. PubMed ID: 27128617
[TBL] [Abstract][Full Text] [Related]
10. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
[TBL] [Abstract][Full Text] [Related]
11. High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.
Chaubey J; Shrivastava D; Pawar S; Singh BK; Sharma R; Sinha S
Int J Mycobacteriol; 2020; 9(3):309-312. PubMed ID: 32862166
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
Vīksna A; Sadovska D; Berge I; Bogdanova I; Vaivode A; Freimane L; Norvaiša I; Ozere I; Ranka R
BMC Infect Dis; 2023 Sep; 23(1):638. PubMed ID: 37770850
[TBL] [Abstract][Full Text] [Related]
13. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
[TBL] [Abstract][Full Text] [Related]
14. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
[TBL] [Abstract][Full Text] [Related]
15. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
16. Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.
Dalal A; Pawaskar A; Das M; Desai R; Prabhudesai P; Chhajed P; Rajan S; Reddy D; Babu S; Jayalakshmi TK; Saranchuk P; Rodrigues C; Isaakidis P
PLoS One; 2015; 10(1):e0116798. PubMed ID: 25606853
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
18. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital.
Liu CH; Yang N; Wang Q; Hu YL; Li L; Zhang GY; Zhu B
Respirology; 2011 Aug; 16(6):918-25. PubMed ID: 21564401
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
20. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
